CARsgen Therapeutics

55 articles about CARsgen Therapeutics

• CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

  8/31/2019

  CARsgen Therapeutics Inc. announced the United States Food and Drug Administration has granted orphan drug designation to its investigational CAR-T cell therapy fully human anti-BCMA autologous chimeric antigen receptor T Cells for the treatment of multiple myeloma.

• CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA

  6/19/2019

  CT053 has also received IND clearance from the National Medical Products Administration in China four months ago and is the subject of an ongoing phase I clinical trial.

• CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the NMPA

  3/1/2019

  CARsgen Therapeutics announced that one of its leading drug candidates, CT053 fully human BCMA-CAR-T cell for the treatment of patients suffering from relapsed/refractory multiple myeloma, has received Investigational New Drug clearance from the National Medical Products Administration.

• CARsgen Therapeutics Receives IND Clearance for GPC3-CAR-T Cells from the NMPA

  1/29/2019

  CARsgen Therapeutics today announced that one of its leading drug candidates, humanized GPC3-CAR-T cell for the treatment of patients suffering from GPC3-positive solid tumors, has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA). This marks China's first IND clearance for CAR-T cells against solid tumors.

• CARsgen Presents Preliminary Results of CAR-BCMA T Cell Therapy at ASH 2018

  12/4/2018

  CARsgen Therapeutics presented initial safety and efficacy results from its ongoing investigational study of CT053 for patients with relapsed/refractory multiple myeloma (R/R MM) at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego.

• CARsgen Presents CAR-Claudin18.2-T Data at 2018 CAR-TCR Summit

  9/8/2018

  CARsgen Therapeutics presented its preliminary clinical data of a first-in-class CAR-Claudin18.2 T cell trial for treatment of pancreatic and gastric cancer at 2018 CAR-TCR Summit in Boston.

• CARsgen Appoints Dr. Hong MA as Senior Vice President of Clinical Development

  8/27/2018

  CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, announced appointment of Dr. Hong Ma as Senior Vice President, Clinical Development.

• CARsgen Completed $60 Million Pre-C Financing Framework Agreements

  3/2/2018

  CARsgen Therapeutics announces it has entered into a Pre-C financing framework agreement with receiving $60M equity investment from existing and new investors.

• CARsgen Therapeutics Launches First-In-Class Anti-Claudin18.2 CAR-T Clinical Trial

  8/10/2017

• CARsgen Therapeutics Announces Next-Generation Safety Switch Technology Published In Molecular Therapy

  7/7/2017

• CARsgen Therapeutics Joins The Alliance For Regenerative Medicine

  6/30/2017

• BIO2017 CARsgen Therapeutics Presented At The 2017 BIO International Convention

  6/23/2017

• CARsgen Therapeutics Presents Phase I Results Of CAR-GPC3 T HCC Trial At ASCO 2017 Annual Meeting

  6/5/2017

• CARsgen Therapeutics Opens CAR T-Cell Manufacturing Facility In Shanghai

  5/3/2017

• CARsgen Therapeutics Completes $30 Million Series B Financing

  1/25/2016